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Abstract: Peroxiredoxin 6 (Prdx6, 1-cys peroxiredoxin) is a unique member of the peroxiredoxin
family that, in contrast to other mammalian peroxiredoxins, lacks a resolving cysteine and uses
glutathione and pi glutathione S-transferase to complete its catalytic cycle. Prdx6 is also the only
peroxiredoxin capable of reducing phospholipid hydroperoxides through its glutathione peroxidase
(Gpx) activity. In addition to its peroxidase activity, Prdx6 expresses acidic calcium-independent
phospholipase A2 (aiPLA2) and lysophosphatidylcholine acyl transferase (LPCAT) activities in
separate catalytic sites. Prdx6 plays crucial roles in lung phospholipid metabolism, lipid peroxidation
repair, and inflammatory signaling. Here, we review how the distinct activities of Prdx6 are regulated
during physiological and pathological conditions, in addition to the role of Prdx6 in cellular signaling
and disease.
Keywords: glutathione peroxidase; phospholipase A2; inflammation; lipid peroxidation; NADPH
(nicotinamide adenine dinucleotide phosphate) oxidase; phospholipid hydroperoxide
1. Introduction
Peroxiredoxins are a ubiquitous family of highly conserved enzymes that share a catalytic
mechanism in which a redox-active (peroxidatic) cysteine residue in the active site is oxidized by a
peroxide [1]. In peroxiredoxins 1–5 (2-cys peroxiredoxins), the resulting sulfenic acid then reacts with
another (resolving) cysteine residue, forming a disulfide that is subsequently reduced by an appropriate
electron donor to complete a catalytic cycle [2,3]. In contrast to peroxiredoxins 1–5, peroxiredoxin 6
(Prdx6, 1-cys peroxiredoxin) lacks a resolving cysteine and uses glutathione (GSH) to complete its
catalytic peroxidatic reaction [4,5]. Aside from the mammalian Prdx6, 1-cys peroxiredoxins that use
GSH as the resolving thiol have been described in yeast [6].
Prdx6 is the only mammalian peroxiredoxin capable of reducing phospholipid hydroperoxides
through its glutathione peroxidase (Gpx) activity, in addition to reducing short chain
hydroperoxides [7]. Moreover, Prdx6 also expresses acidic calcium-independent phospholipase
A2 (aiPLA2) and lysophosphatidylcholine acyl transferase (LPCAT) activities in separate catalytic
sites [8,9]. Therefore, Prdx6 is a multi-tasking enzyme that participates in cellular signaling by
modulating several pathways through its peroxidase, aiPLA2, and LPCAT activities. The three activities
of Prdx6 are differentially regulated by the subcellular localization of the protein, substrate binding,
and post-translational modifications [10]. Differential expression of the enzymatic activities of Prdx6
appears to have contrasting roles in several pathologies. Here, we review the current knowledge of the
role of Prdx6 in cellular signaling. This publication is part of a forum on Prdx6 as a unique member of
the peroxiredoxin family.
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2. Regulation of the Enzymatic Activities of Prdx6
The subcellular localization of Prdx6 is crucial for the regulation of its enzymatic activities.
Prdx6 exhibits maximal aiPLA2 activity at an acidic pH and maximal peroxidase activity at a neutral
pH [10]. Hence, when Prdx6 is localized in lysosomal-type organelles such as lamellar bodies in type II
pneumocytes, it functions as an aiPLA2, contributing to lung phospholipid metabolism [11]. In contrast,
cytosolic Prdx6 functions mainly as a peroxidase under basal conditions [4]. Aside from the cytosol and
lysosomal-type organelles, Prdx6 can move to the mitochondria, the plasma membrane, and possibly
other organelles, after cellular stimulation with different agonists [12,13]. Prdx6 translocation to the
mitochondria controls oxidative stress in the initial step of PINK1/Parkin-mediated mitophagy [14].
Prdx6 translocation to the plasma membrane has several biological effects involving its peroxidase and
aiPLA2 activities, which will be described in detail in this manuscript. Prdx6 has also been detected
in extracellular fluids, including plasma, bronchoalveolar lavage, and cerebrospinal fluid, but it is
unknown whether extracellular Prdx6 functions as a peroxidase or as an aiPLA2 [11,15,16].
Several post-translational modifications regulate the enzymatic activities of Prdx6 by promoting
changes in the intracellular localization of the protein or inactivating one or both catalytic sites.
The phosphorylation of Prdx6 at threonine 177 by p38 mitogen-activated protein kinase (MAPK),
after stimulation with phorbol ester, angiotensin II, or shear stress, induces a conformational change in
the protein, promotes its translocation to the plasma membrane, and increases its aiPLA2 activity [12,17].
Prdx6 is also phosphorylated in a circadian manner, suggesting that a switch between peroxidase
and aiPLA2 activities may occur naturally [18]. Similarly, MAPK activity is required for the targeting
of Prdx6 to lysosomal-type organelles, which occurs through the binding of Prdx6 to the chaperone
protein 14-3-3ε [19–21]. The hyperoxidation of Prdx6 at cysteine 47 inactivates the Gpx activity while
increasing aiPLA2. In contrast to the hyperoxidation of 2-cys peroxiredoxins, the hyperoxidation of
Prdx6 is irreversible [22]. The glutathionylation of Prdx6 by pi GSH S-transferase (piGST) is required
for the reduction of the oxidized cysteine and the completion of the peroxidatic catalytic cycle [23].
Prdx6 can also be aberrantly Sumoylated by Sumo1 at lysines 122 and 142 during oxidative stress.
Aberrant sumoylation of Prdx6 reduces its gene expression and protein abundance [24–26].
The binding of Prdx6 to different substrates differentially regulates its GPx and aiPLA2 activities.
At an acidic pH, when aiPLA2 is maximal, Prdx6 binds to reduced phospholipids. In contrast,
Prdx6 binds only to oxidized phospholipids at cytosolic pH. The binding of Prdx6 to oxidized
phospholipids requires the translocation of Prdx6 from the cytosol to the cell membrane, and has been
observed after treating live cells with peroxides [11,27–30]. Cytosolic Prdx6 could also potentially
translocate to oxidized intracellular organelle membranes, but this idea remains unexplored.
Aside from posttranslational modifications and subcellular localization, the enzymatic activities
of Prdx6 can be regulated by interactions with other proteins. The direct interaction of Prdx6 with
the surfactant protein A (SP-A) suppresses aiPLA2 in a process that is important for the regulation
of lung phospholipid metabolism in lamellar bodies of type II pneumocytes [31–33]. Similarly,
the interaction of Prdx6 with LIMP2 likely facilitates the binding of Prdx6 to phospholipids in acidic
environments [34]. As described above, the binding of Prdx6 to piGST is necessary for the reduction
of the oxidized cysteine and thus for the completion of the peroxidatic catalytic cycle, but not for
aiPLA2 activity [23,35,36]. Prdx6 can also interact with the NADPH oxidase (Nox) subunits p67phox
and Noxa1 [37,38]. These interactions seem to be necessary for optimal Nox activity. Interaction of
phosphorylated Prdx6 with p67phox inhibits aiPLA2 and appears to be the mechanism that terminates Nox
activation [39].
3. Signaling by Prdx6 Peroxidase
Peroxiredoxins are well known for their role in cellular signaling as hydrogen peroxide (H2O2)
sensors. As mentioned above, Prdx6 is the only peroxiredoxin capable of reducing phospholipid
hydroperoxides in addition to reducing H2O2 and short-chain peroxides. Hydroperoxide reduction
occurs in three steps: peroxidation (the reduction of the hydroperoxide, which oxidizes the cysteine
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to sulfenic acid), resolution (the reduction of sulfenic acid), and recycling (the regeneration of the
cysteine active site) [40,41]. This process occurs at the conserved cysteine 47 catalytic site and requires
glutathione and piGST [5,36].
Lipid peroxidation products such as malondialdehyde (MDA) and 4-hydroxynonenal (4HNE)
have traditionally been viewed as toxic byproducts implicated in the etiology of several diseases [42–45].
However, increasing evidence shows that MDA and 4HNE also elicit biological activities that result
in anti-inflammatory and pro-survival effects such as Nrf2 activation and UCP3 upregulation [46,47].
Therefore, lipid hydroperoxide reduction by Prdx6 is crucial to limit peroxidation-derived pathological
effects and to regulate adaptive responses mediated by electrophilic lipid peroxidation products.
The only other enzyme known to be able to reduce phospholipid hydroperoxides in mammalian cells is
glutathione peroxidase 4 (Gpx4) [48,49]. The expression of Prdx6 and Gpx4 likely varies among tissues,
cell types, and possibly developmental stages and disease progression, but it is currently unknown
if these two proteins exhibit complementary functions or if one replaces the other in particular
pathophysiological conditions.
As described above, Prdx6 is recruited to peroxidized cell membranes following oxidative stress,
where it reduces and hydrolyzes the oxidized sn-2 fatty acyl or the sn-2 ester (alkyl) bond of oxidized
phospholipids through its GPx and aiPLA2 activities [30,50]. Thus, Prdx6 actively participates in the
prevention and repair of lipid peroxidation. The critical role of both the GPx and aiPLA2 activities
of Prdx6 in the repair of lipid peroxidation has been extensively demonstrated in cells, lungs, and
knock-in mouse models that express either Prdx6 GPx or aiPLA2 activity after treatment with peroxides
and exposure to paraquat or hyperoxia [28,29,51].
A novel lysophosphatidylcholine acyl transferase (LPCAT) activity of Prdx6 coupled to aiPLA2
was recently described [9]. Prdx6 LPCAT acylates lysophosphatidylcholine (LPC) generated by aiPLA2
in a continuous process, without the release of the LPC intermediate generated by aiPLA2. Thus,
LPCAT and aiPLA2 combine to replace an oxidized acyl chain with palmitoyl CoA, effectively repairing
oxidized cell membranes. Hence, Prdx6 possesses the ability to reduce peroxidized cell membrane
phospholipids through its GPx activity and to replace the oxidized sn-2 fatty acyl group through
hydrolysis/reacylation by aiPLA2 and LPCAT, providing a complete system for the repair of
peroxidized cell membranes [30].
The recent discovery of ferroptosis, a distinct cell death pathway characterized by the intracellular
accumulation of lipid hydroperoxides [52–55], is generating increasing interest in the role of lipid
peroxidation in the progression of several diseases. The role of GPx4, the only other enzyme capable
of reducing lipid hydroperoxides, is evident in ferroptosis [54,55]. In contrast, the role of Prdx6 as a
regulator of ferroptosis has not been studied, but undoubtedly warrants further investigation.
4. Signaling by aiPLA2
Studies using Prdx6 knock-in and knock-out mice, intact lung preparations and primary cells,
and an aiPLA2 inhibitor (MJ33) show that, aside from its role in lung phospholipid metabolism, aiPLA2
is necessary for the activation of NADPH oxidase 2 (Nox2) during stimulation with phorbol ester,
shear stress, angiotensin II, N-formylmethionine-leucyl-phenylalanine, or endotoxin [12,37,56–60].
The mechanism by which Prdx6 regulates Nox2 starts with the p38 MAPK-mediated phosphorylation
of Prdx6, its translocation to the plasma membrane, and the generation of LPC by aiPLA2. LPC is
then converted to lysophosphatidic acid (LPA) by lysophospholipase D. LPA signals through LPA
receptors, activating the small GTPase Rac which moves from the cytosol to the membrane to activate
Nox2 [12,60,61].
Initial studies discovered a direct interaction of Prdx6 with p67phox, a cytosolic component of
Nox2, and suggested that aiPLA2 plays a critical role in Nox2 activation [56]. Later studies showed that
binding occurs only between phosphorylated Prdx6 and non-phosphorylated p67phox and that such an
interaction suppresses aiPLA2, likely terminating Nox2 activity [39]. Contrasting evidence exists about
the role of Prdx6 in the regulation of other members of the NADPH oxidase family. On the one hand,
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MJ33 did not inhibit angiotensin II-stimulated oxidant generation in human pulmonary smooth muscle
cells, which express high levels of NADPH oxidase 1 (Nox1) [58]. On the other hand, recent evidence
showed that Prdx6 binds to Noxa1, a regulator of Nox1, and that knockdown of Prdx6 or inhibition of
aiPLA2 with MJ33 blunts Nox1-derived oxidant generation and suppresses cell migration [38].
NADPH oxidases are important activators of redox-dependent inflammatory pathways [62].
Thus, aiPLA2 signaling plays a role in inflammation by regulating Nox-derived oxidant
generation. The inhibition of aiPLA2 with MJ33 protects the lungs from hyperoxia, endotoxin,
and ischemia/reperfusion injury by blunting oxidant generation and preventing inflammation [58,59,63].
Our unpublished observations suggest that knock-in mice deficient in aiPLA2 are resistant to
sepsis-induced acute lung injury. Signaling effects of aiPLA2, independent from the regulation
of NADPH oxidases such as the generation of inflammatory mediators derived from arachidonic
acid, have been proposed [64,65]. aiPLA2, however, does not show a preference for arachidonic
acid-containing phospholipids [66,67]. Therefore, it is unclear how aiPLA2 could regulate inflammatory
pathways derived from arachidonic acid release.
5. Prdx6 Signaling in Disease
5.1. Cancer
Peroxiredoxins have a dual role in carcinogenesis, acting as both tumor suppressors and
promoters [68–70]. Such a dual role appears to be consistent with the established role of oxidants
in both cell proliferation and death [68,71,72]. Increased Prdx6 levels have been detected in various
cancers, and the role of Prdx6 in lung cancer invasion is well known [73]. aiPLA2 promotes cell
invasion and metastasis in various models, likely through the regulation of NADPH oxidase, which is
needed for cell proliferation [74]. Mice that over-express Prdx6 show a greater increase in the growth
of lung tumors compared to wild-type animals. Both aiPLA2 and Prdx6 peroxidase activities are
implicated in lung tumor development through the regulation of redox-sensitive pathways such as
MAPK, JNK, JAK/STAT, and AP-1 [75–77].
5.2. Inflammation
Prdx6 appears to have a dual role in inflammatory disease. One the one hand, as described above,
aiPLA2 is necessary for the activation of the pro-inflammatory NADPH oxidase. On the other hand,
Prdx6 is crucial to counteract increased reactive oxygen species (ROS) generation and to repair oxidized
cell membranes following oxidative stress. Hyperoxidized Prdx6 levels are high in the peripheral blood
mononuclear cells of moderate-to-severe asthma patients, where ROS generation is also elevated [78].
Moreover, LPS-treated Prdx6-over-expressing mice show less renal apoptosis and leukocyte infiltration
than wild-type controls [79]. Similarly, Prdx6 null mice show increased lung inflammation after
intratracheal instillation of lipopolysaccharide (LPS) [80]. Lung inflammation and mortality induced
by paraquat or hyperoxia are also increased in Prdx6 null mice [81,82]. In contrast, Prdx6 null mice
show reduced inflammation, but increased hepatic oxidative damage and mitochondrial dysfunction
after experimental ischemia/reperfusion [83]. Moreover, the inhibition of aiPLA2 with MJ33 reduces
inflammation after hyperoxia or intratracheal LPS exposure [59,63]. Therefore, it is likely that Prdx6
plays a dual role in inflammatory conditions, both as an activator of inflammatory pathways related
to NADPH oxidase through aiPLA2 and as a protective/regulatory mechanism through Prdx6
peroxidase activity.
The link between Prdx6 and NfκB, which is one of the most prominent redox-regulated
pro-inflammatory regulators, has been known for some time [84]. Prdx6 protects against
ischemia/reperfusion injury during liver transplantation by downregulating NfκB [85]. Similarly,
Prdx6 expression is inversely correlated with NfκB during Clonorchis sinensis infection [86].
In contrast, extracellular Prdx6 signals through a toll-like receptor (TLR) after focal cerebral
ischemia/reperfusion [87]. Other extracellular oxidized peroxiredoxins released via the exosomal
Antioxidants 2018, 7, 172 5 of 12
pathway can bind to TLR, contributing to sustained inflammatory responses that involve NfκB
signaling. The specific role of Prdx6 in this process, however, remains unknown [88]. Our unpublished
observations show that the genetic inactivation (knock-in) of aiPLA2 prevents the nuclear translocation
of NfκB in lung endothelial cells stimulated with LPS. Thus, it appears that Prdx6 peroxidase and
aiPLA2 may play contrasting roles in NfκB signaling.
5.3. Metabolic Disease
Prdx6 is linked to the development of type 2 diabetes. Prdx6 null mice show low insulin and
elevated blood glucose levels, compared to wild-type mice, after a glucose tolerance test. Similarly,
insulin signaling and pancreatic β cell morphology are impaired in Prdx6 knockout mice. Moreover,
Prdx6 null mice develop dyslipidemia [89]. Prdx6 appears to also be linked to the generation of
hydroxy fatty acids, which are antidiabetic/anti-inflammatory lipid mediators synthesized in white
adipose tissue via de novo lipogenesis [90]. The specific role of Prdx6 peroxidase and aiPLA2 activities
in the development and progression of metabolic disease remains unexplored.
5.4. Ocular Damage
The role of Prdx6 in ocular oxidative damage has been extensively investigated [91,92].
Prdx6 expression in the eye declines with age, increasing the risk of cataract formation [26,93,94].
Moreover, Prdx6 prevents oxidative stress in human retinal pigment epithelial cells by activating the
Phosphoinositide 3-kinase/Protein kinase B (PI3K/AKT) pathway [95] and blunting transforming
growth factor beta (TGF-β) signaling [96]. Prdx6 is therefore necessary to prevent cataract formation
and to limit aging-induced oxidative stress in the eye. The exposure of human lens epithelial
cells to ultraviolet-B light results in Prdx6 hyperoxidation, increased ROS generation, and cellular
toxicity [92,97]. The function of Prdx6 in the eye is the topic of a separate review article, which is part
of this forum.
5.5. Brain Injury and Neurodegeneration
The role of Prdx6 in neurodegenerative diseases is controversial [98]. Following a traumatic
brain injury, oxidized Prdx6 is detected in the cerebrospinal fluid [16,99]. Moreover, Prdx6 signaling
through TLR4 increases after an ischemic stroke, leading to NfκB-mediated inflammation and cell
death [87,100,101]. Similarly, the pharmacological inhibition of aiPLA2 with MJ33 reduces inflammation
in an experimental stroke model, supporting the idea that aiPLA2 has a pro-inflammatory role in the
brain under such conditions [102].
The impairment of brain neurogenesis is linked to Alzheimer’s (AD) and Parkinson’s disease
(PD) [103,104]. Recent work shows that Prdx6 has an inhibitory effect on neurogenesis [105]. In contrast,
Prdx6 reduces oxidative stress and counteracts ROS generation, suggesting that Prdx6 plays a
neuroprotective role in AD models [103]. Similarly, Prdx6 reduces inflammation and protects against
disruption to the blood–brain barrier in a model of multiple sclerosis [106]. Prdx6 hyperoxidation is
observed in a PD mouse model [104]. As discussed above, the hyperoxidation of Prdx6 is irreversible,
and inactivates the Gpx function. Therefore, the dual role of Prdx6 in neurodegeneration seems to be
linked to the differential expression of Prdx6 peroxidase and aiPLA2 activities.
5.6. Male Infertility
Prdx6 plays a crucial role in spermatozoon fertilizing ability [107,108]. Lower levels of Prdx6 are
associated with impaired sperm function and poor DNA integrity in infertile men [109]. Sperm motility,
viability, fertilization, and blastocyst rates are lower in Prdx6 null mice than they are in wild-type
controls [110]. The role of Prdx6 in male fertility is extensively discussed in a separate review article,
which is part of this forum.
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6. Conclusions and Future Directions
Prdx6 is an intriguing enzyme that contributes to the regulation of a plethora of signaling
pathways related to its diverse catalytic activities. The contrasting biological roles of Prdx6 are
likely explained by the delicate differential expression of its peroxidase and aiPLA2 activities.
Further investigations on the role of Prdx6 in cell signaling should focus on understanding the
mechanisms that control the shift between Prdx6 peroxidase and aiPLA2 activities under physiological
and pathological conditions. Similarly, the role of extracellular Prdx6 in inflammatory signaling remains
underexplored. Moreover, the role of Prdx6 as a complete lipid peroxidation repair enzyme warrants
further studies to elucidate how Prdx6 regulates cellular signaling by lipid peroxidation products,
as well as the possible role of Prdx6 in novel pathways of cell death.
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